Annual EBIT
-$117.91 M
-$32.44 M-37.95%
31 December 2023
Summary:
Cara Therapeutics annual earnings before interest & taxes is currently -$117.91 million, with the most recent change of -$32.44 million (-37.95%) on 31 December 2023. During the last 3 years, it has fallen by -$123.29 million (-2289.58%). CARA annual EBIT is now -2289.58% below its all-time high of $5.59 million.CARA EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly EBIT
-$10.52 M
+$7.59 M+41.92%
30 September 2024
Summary:
Cara Therapeutics quarterly earnings before interest & taxes is currently -$10.52 million, with the most recent change of +$7.59 million (+41.92%) on 30 September 2024. Over the past year, it has increased by +$17.52 million (+62.49%). CARA quarterly EBIT is now -113.43% below its all-time high of $78.29 million, reached on 31 December 2020.CARA Quarterly EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM EBIT
-$89.07 M
+$17.52 M+16.43%
30 September 2024
Summary:
Cara Therapeutics TTM earnings before interest & taxes is currently -$89.07 million, with the most recent change of +$17.52 million (+16.43%) on 30 September 2024. Over the past year, it has increased by +$26.35 million (+22.83%). CARA TTM EBIT is now -491.87% below its all-time high of $22.73 million, reached on 30 September 2021.CARA TTM EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
CARA EBIT Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -38.0% | +62.5% | +22.8% |
| 3 y3 years | -2289.6% | -835.6% | -491.9% |
| 5 y5 years | -52.4% | +69.5% | +14.1% |
CARA EBIT High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -2289.6% | at low | -835.6% | +68.0% | -491.9% | +25.8% |
| 5 y | 5 years | -2289.6% | at low | -113.4% | +69.5% | -491.9% | +25.9% |
| alltime | all time | -2289.6% | at low | -113.4% | +69.5% | -491.9% | +25.9% |
Cara Therapeutics EBIT History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | -$10.52 M(-41.9%) | -$89.07 M(-16.4%) |
| June 2024 | - | -$18.11 M(-36.9%) | -$106.58 M(-11.1%) |
| Mar 2024 | - | -$28.71 M(-9.5%) | -$119.96 M(+1.7%) |
| Dec 2023 | -$117.91 M(+37.9%) | -$31.73 M(+13.2%) | -$117.91 M(+2.2%) |
| Sept 2023 | - | -$28.03 M(-11.0%) | -$115.42 M(+3.8%) |
| June 2023 | - | -$31.48 M(+18.1%) | -$111.23 M(+32.1%) |
| Mar 2023 | - | -$26.66 M(-8.8%) | -$84.23 M(-1.5%) |
| Dec 2022 | -$85.47 M(-3.4%) | -$29.25 M(+22.7%) | -$85.47 M(-4.1%) |
| Sept 2022 | - | -$23.84 M(+433.2%) | -$89.11 M(+34.2%) |
| June 2022 | - | -$4.47 M(-84.0%) | -$66.39 M(-28.5%) |
| Mar 2022 | - | -$27.91 M(-15.1%) | -$92.79 M(+4.9%) |
| Dec 2021 | -$88.44 M(-1742.4%) | -$32.88 M(+2825.3%) | -$88.44 M(-489.1%) |
| Sept 2021 | - | -$1.12 M(-96.4%) | $22.73 M(+232.6%) |
| June 2021 | - | -$30.88 M(+31.0%) | $6.83 M(-42.2%) |
| Mar 2021 | - | -$23.56 M(-130.1%) | $11.82 M(+119.6%) |
| Dec 2020 | $5.38 M(-104.8%) | $78.29 M(-560.0%) | $5.38 M(-105.2%) |
| Sept 2020 | - | -$17.02 M(-34.2%) | -$102.88 M(-14.5%) |
| June 2020 | - | -$25.88 M(-13.7%) | -$120.29 M(+1.5%) |
| Mar 2020 | - | -$30.00 M(+0.1%) | -$118.55 M(+6.1%) |
| Dec 2019 | -$111.68 M(+44.3%) | -$29.97 M(-13.0%) | -$111.68 M(+7.7%) |
| Sept 2019 | - | -$34.43 M(+42.6%) | -$103.69 M(+15.6%) |
| June 2019 | - | -$24.14 M(+4.4%) | -$89.72 M(+7.6%) |
| Mar 2019 | - | -$23.13 M(+5.3%) | -$83.39 M(+7.8%) |
| Dec 2018 | -$77.38 M | -$21.98 M(+7.4%) | -$77.38 M(+10.6%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2018 | - | -$20.47 M(+14.9%) | -$69.98 M(+12.0%) |
| June 2018 | - | -$17.81 M(+4.0%) | -$62.46 M(+15.1%) |
| Mar 2018 | - | -$17.12 M(+17.5%) | -$54.28 M(-8.7%) |
| Dec 2017 | -$59.48 M(+1.9%) | -$14.57 M(+12.5%) | -$59.48 M(-11.5%) |
| Sept 2017 | - | -$12.96 M(+34.5%) | -$67.23 M(+1.8%) |
| June 2017 | - | -$9.63 M(-56.9%) | -$66.05 M(-5.3%) |
| Mar 2017 | - | -$22.32 M(+0.0%) | -$69.74 M(+19.4%) |
| Dec 2016 | -$58.40 M(+131.9%) | -$22.32 M(+89.5%) | -$58.40 M(+27.5%) |
| Sept 2016 | - | -$11.77 M(-11.7%) | -$45.81 M(+17.3%) |
| June 2016 | - | -$13.33 M(+21.3%) | -$39.05 M(+24.1%) |
| Mar 2016 | - | -$10.99 M(+12.9%) | -$31.46 M(+24.9%) |
| Dec 2015 | -$25.19 M(+39.4%) | -$9.73 M(+94.2%) | -$25.19 M(+27.2%) |
| Sept 2015 | - | -$5.01 M(-12.6%) | -$19.80 M(-7.5%) |
| June 2015 | - | -$5.73 M(+21.5%) | -$21.39 M(+10.4%) |
| Mar 2015 | - | -$4.72 M(+8.8%) | -$19.37 M(+7.2%) |
| Dec 2014 | -$18.07 M(+7525.3%) | -$4.34 M(-34.3%) | -$18.07 M(+14.1%) |
| Sept 2014 | - | -$6.60 M(+77.9%) | -$15.84 M(+24.0%) |
| June 2014 | - | -$3.71 M(+8.5%) | -$12.78 M(+494.9%) |
| Mar 2014 | - | -$3.42 M(+62.5%) | -$2.15 M(+806.3%) |
| Dec 2013 | -$237.00 K(-96.2%) | -$2.10 M(-40.6%) | -$237.00 K(-339.4%) |
| Sept 2013 | - | -$3.54 M(-151.2%) | $99.00 K(-97.3%) |
| June 2013 | - | $6.92 M(-558.2%) | $3.64 M(-211.0%) |
| Mar 2013 | - | -$1.51 M(-14.6%) | -$3.28 M(+85.4%) |
| Dec 2012 | -$6.24 M(-34.8%) | -$1.77 M | -$1.77 M |
| Dec 2011 | -$9.57 M | - | - |
FAQ
- What is Cara Therapeutics annual earnings before interest & taxes?
- What is the all time high annual EBIT for Cara Therapeutics?
- What is Cara Therapeutics annual EBIT year-on-year change?
- What is Cara Therapeutics quarterly earnings before interest & taxes?
- What is the all time high quarterly EBIT for Cara Therapeutics?
- What is Cara Therapeutics quarterly EBIT year-on-year change?
- What is Cara Therapeutics TTM earnings before interest & taxes?
- What is the all time high TTM EBIT for Cara Therapeutics?
- What is Cara Therapeutics TTM EBIT year-on-year change?
What is Cara Therapeutics annual earnings before interest & taxes?
The current annual EBIT of CARA is -$117.91 M
What is the all time high annual EBIT for Cara Therapeutics?
Cara Therapeutics all-time high annual earnings before interest & taxes is $5.59 M
What is Cara Therapeutics annual EBIT year-on-year change?
Over the past year, CARA annual earnings before interest & taxes has changed by -$32.44 M (-37.95%)
What is Cara Therapeutics quarterly earnings before interest & taxes?
The current quarterly EBIT of CARA is -$10.52 M
What is the all time high quarterly EBIT for Cara Therapeutics?
Cara Therapeutics all-time high quarterly earnings before interest & taxes is $78.29 M
What is Cara Therapeutics quarterly EBIT year-on-year change?
Over the past year, CARA quarterly earnings before interest & taxes has changed by +$17.52 M (+62.49%)
What is Cara Therapeutics TTM earnings before interest & taxes?
The current TTM EBIT of CARA is -$89.07 M
What is the all time high TTM EBIT for Cara Therapeutics?
Cara Therapeutics all-time high TTM earnings before interest & taxes is $22.73 M
What is Cara Therapeutics TTM EBIT year-on-year change?
Over the past year, CARA TTM earnings before interest & taxes has changed by +$26.35 M (+22.83%)